The Firefinch Ltd (AXX: FFX) share price is falling this morning after the company released a potentially disappointing clarification.

Firefinch excited the market yesterday when the company announced details surrounding its inclusion in the VanEck Junior Gold Miners ETF (NYSE: GDXJ) on Twitter (NYSE: TWTR).

However, the gold miner and lithium developer has clarified that it didn’t authorise the tweet and investors shouldn’t rely on the information it contained.

Right now, the Firefinch share price is 67 cents, 1.47% lower than its previous close.

Let’s take a closer look at today’s news from Firefinch.

Firefinch share price slides following clarification of tweet

The Firefinch share price is in the red today following the company’s clarification of a since-deleted tweet.

Firefinch claims a contractor tweeted the GDXJ ETF will be spending a certain amount to buy Firefinch stock this week. The company also stated it didn’t approve the tweet.

According to reporting by Proactive Investors, which was shared by Firefinch’s LinkedIn account yesterday, the company was recently added to the ETF. However, the report said the fund is yet to purchase the shares needed to reach its allocated holding.

The Firefinch contractor is said to have put two and two together. They posted to Twitter the amount the ETF might spend to receive its allocated hold in Firefinch.

The Firefinch share price gained 9% amid the tweet’s publication yesterday.

Interestingly, while Firefinch has deleted the contentious tweet, a post on the company’s LinkedIn page still reads: “[T]he GDXJ EFT will have to purchase [$30 million] worth of [Firefinch] stock [by Friday’s close]”.

Further, the company’s clarification didn’t deny the validity of the information within the tweet. Instead, it warned investors not to rely on the information.

However, the company’s addition to the GDXJ ETF might not have caused all its gains yesterday. Firefinch also released its half-year results on Monday. The results may also have been responsible for a decent portion of the Firefinch share price increase.

The post Firefinch (ASX:FFX) share price slides following tweet clarification appeared first on The Motley Fool Australia.

More reading

• Firefinch (ASX:FFX) share price leaps 16% on half-year results

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Twitter. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3huaoPa

The Pointerra Ltd (ASX: 3DP) share price is rocketing in morning trade, up 21% to 44 cents per share.

Earlier today the 3D geospatial data technology company released its corporate presentation. We look at a few highlights below.

What did Pointerra present?

Investors may be bidding up the Pointerra share price after the company reported annual contract value (ACV) growth of 240%. ACV increased from $2.9 million from July 2020 to $9.8 million reported as at July 2021.

Meanwhile cash receipts from its customers reached $4.1 million for the full 2021 financial year (FY21), up from $1.8 million in FY20. The company reported cash receipts of $1.4 million in Q4 FY21 alone.

Pointerra also expanded its full-time employees from 12 to 29.

The company credited ACV growth to “customer-led engagement, focused on solving workflow problems and ‘automating the manual’”. It said its existing customers continued to increase their spending, with very low churn rate.

The United States utility sector counts among its leading customers. Pointerra is directly contracting with utilities as well as with their mapping providers. The company said:

Pointerra has combined advanced machine learning algorithms for automatically extracting valuable information from 3D data with extensive browser-based manual feature identification/editing tools.

Mining companies also are turning to Pointerra’s technology platform.

The Pointerra share price may also be getting a boost as the company reported it is collaborating with the US Department of Defense. It said it is “responding to the requirement to constantly enhance the capability of the modern war fighter through the use of technology”.

Pointerra reported the solution to modern defence needs is, “Automated analytics that fuses newly acquired and historic 3D spatial data and delivers insight in real-time to support informed decision making.”

Pointerra share price snapshot

The Pointerra share price has been under pressure in 2021, down 15% year-to-date. By comparison the All Ordinaries Index (ASX: XAO) is up 11% in that same time.

Over the past month Pointerra shares have gained 7%.

The post Pointerra (ASX:3DP) share price leaps 21% as cash receipts surge appeared first on The Motley Fool Australia.

More reading

• Pointerra (ASX:3DP) share price 5% higher on triple-digit revenue growth in FY21
• 3 exciting small cap ASX shares to watch closely
• Pointerra (ASX:3DP) share price leaps 8% ahead of next week’s earnings

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pointerra Limited. The Motley Fool Australia has recommended Pointerra Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3Ab41aT

The Fortescue Metals Group Limited (ASX: FMG) share price is struggling to push higher this week as new steel production curbs in China continues to cripple iron ore prices.

At the time of writing, shares in the iron ore major are down 1.85% to $18.07.

Fortescue share price threatens 10-month lows

Iron ore prices tanked another 4.5% on Monday to US$123.84/t due to weak buying interest, according to Fastmarkets MB.

China’s iron ore demand is expected to weaken in the second half of the year after policymakers vowed to limit crude steel output to curb industrial pollution.

On Monday, Reuters reported further output curbs on various commodities including aluminium, steel and cement.

“As of August, Yunnan aluminium smelters had already shut down nearly 1 million tonnes of annual capacity due to power curbs, state-backed research house Antaike said earlier this month. “

The Yunnan province, which is home to around 2.3% of China’s total crude steel output was also asked to curtail production.

“The local government asked Yunnan steel mills to adjust production schedules while ensuring that its 2021 crude steel output falls, according to the document.”

“Part of the planned September crude steel production would be postponed to the last two months of the year,” it added.

More broadly speaking, Reuters said that “Beijing has warned two-thirds of China’s provinces and territories for missing their [energy] intensity targets in the first half of the year.”

What does this mean for Fortescue?

According to Fortescue’s annual report, the Platts 62% iron ore price averaged US$154/dry metric tonne (dmt) in FY21.

Fortescue’s lower grade iron ore managed to achieve a realised price of US$135/dmt, increasing by 72% over the prior year.

With current spot prices well below Platt’s FY21 average, this could spell a cloudy outlook for Fortescue.

Fortescue share price tumbles in 2021

The Fortescue share price has cratered amidst the sharp decline in iron ore prices, down 27% year-to-date.

The post Fortescue (ASX:FMG) share price struggles amid new production curbs in China appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Fortescue (ASX:FMG) shares bounce off 9-month low as iron ore sell-off continues
• The Fortescue (ASX:FMG) share price is down 13% so far this month
• How have ASX resources shares performed during the August 2021 earnings season?
• These were the worst performing ASX 200 (ASX:XJO) shares last week

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3EgVgOM

The Telstra Corporation Ltd (ASX: TLS) share price certainly has been on form this year.

The telco giant’s shares have risen an impressive 31% year to date to $3.95.

Where next for the Telstra share price?

The good news is that one leading broker is tipping the Telstra share price to keep rising.

According to a note out of Goldman Sachs, its analysts have retained their buy rating and lifted their price target on the telco giant’s shares to $4.40.

Based on the current Telstra share price, this implies potential upside of 11% over the next 12 months before dividends.

And if you throw in the 16 cents per share fully franked dividend Goldman expects in FY 2022, the potential return increases to over 15%.

What did the broker say?

Goldman Sachs remains positive on the Telstra share price due to its belief that its key mobile business and cost reductions will underpin solid growth in the coming years.

The broker expects this to lead to earnings per share of 15 cents in FY 2022, 18 cents in FY 2023, and then 20 cents in FY 2024. The latter is expected to allow the company to lift its dividend for the first time in over a decade.

Goldman is forecasting dividends of 16 cents per share through to FY 2023 before an increase to 18 cents per share in FY 2024. Based on the current Telstra share price, this will mean yields of 4% and then 4.6%.

Anything else?

The broker also highlights that Telstra will be holding its Strategy for the Future Investor Day event this week. This strategy is expected to provide investors with an idea of its plans beyond its highly successful T22 strategy.

It commented: “Ahead of the much anticipated ‘Strategy for the Future’ investor day on Sept 16, we outline our expectations. Strategically we expect a continuation of the current strategy (simplicity and customer focus, network leadership and improved efficiency) but with a tilt towards growth (such as Energy, Health, FWA, Enterprise 5G).”

Goldman also expects updates on earnings targets, dividend plans, InfraCo, and CEO succession planning. The broker notes that “CEO Andrew Penn in his 7th year as CEO of Telstra, we believe commentary around the company’s leadership post T22 could be provided.”

A good update this week could potentially be a catalyst for driving its shares higher. So investors may want to watch that event closely.

The post Why this broker sees 11% upside in the Telstra (ASX:TLS) share price appeared first on The Motley Fool Australia.

More reading

• Leading brokers name 3 ASX shares to buy today
• What to watch at the Telstra (ASX:TLS) Strategy for the Future event this week
• 5 things to watch on the ASX 200 on Monday
• Leading broker says Telstra (ASX:TLS) share price is a buy
• How have ASX telecommunication shares performed during the August 2021 earnings season?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Telstra Corporation Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/2Xl2il3

The Creso Pharma Ltd (ASX: CPH) share price is on the move today, reversing yesterday’s losses. This comes as the cannabis and psychedelics company released a positive update to the ASX on Monday.

During morning trade, Creso shares are swapping hands for 12.5 cents apiece, up 4.17%.

What did Creso announce?

According to its announcement, Creso advised it secured two new purchase orders from Swiss-based health products distributor MHG GmbH (MHG).

The purchase orders consist of Creso’s cannaQIX hemp seed oil lozenges and cannaQIX 50mg lozenges. The human health products are designed to support patients suffering from chronic pain as well as other conditions.

The lozenges dissolve rapidly in the mouth and are absorbed directly into patients’ bloodstreams. This allows the active ingredients to work faster than traditional capsules or tablets.

The value of the shipment is worth around $337,500 and is expected to be delivered as soon as possible.

Creso noted that the new purchase orders represent an important milestone in strengthening its export business. The products are to be sold through MHG sales channels into countries such as Macedonia, Albania, Serbia, and Croatia.

Both companies are collaborating further, discussing additional purchase orders for Creso’s animal health products.

Creso Swiss International Operations CEO Jorge Wernli commented:

We are very pleased to have secured these POs from MHG and it is a clear sign that our export business for human health products is beginning to scale up again. The POs will add to the Company’s growing revenue line, as well as allow Creso Pharma to expand into new countries.

This is a key milestone on our journey and commitment to strengthening Creso Pharma’s export business and geographic expansion, which we anticipate will unlock value for shareholders.

About the Creso share price

It’s been a tough 2021 for Creso shareholders, watching the company’s value fall by more than 30%. However, when looking at the course of the last 12 months, its shares are up 257%.

Based on today’s price, Creso presides a market capitalisation of roughly $150 million, with approximately 1.2 billion shares outstanding.

The post Creso (ASX:CPH) share price edges 4% higher following export deal appeared first on The Motley Fool Australia.

More reading

• Creso Pharma (ASX:CPH) share price jumps 16% on merger termination & NASDAQ plans
• ASX cannabis shares eyeing $63 billion in legal global sales

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3nstSHN

The Cirralto Ltd (ASX: CRO) share price has jumped straight out of the starting blocks on Tuesday morning. This follows the announcement of Cirralto entering an agreement to acquire eCommerce software company, Greenshoots Technology.

At the time of writing, the Cirralto share price is exchanging hands for 6.6 cents a share, up 3.13%. Despite the gain today, shares in the company have slumped 12.3% over the past month.

Let’s run through the details of the Greenshoots acquisition.

eCommerce offering bolstered with Greenshoots

Investors are bidding up the Cirralto share price in early trade after its latest announcement. Already, after only one hour of trade, more than twice the daily average volume has been traded.

According to the release, the company has executed a binding share sale agreement to acquire Greenshoots Technology. The acquiree is a software house that specialises in online retailing technology, providing a white-labelled e-Commerce platform to small and medium-sized businesses.

In the announcement, Cirralto explained that Greenshoots’ intellectual property completes its retail solutions capabilities. After integrating its offerings, the company can focus on eCommerce payments and consumer pay-later services. This is in a bid to capture a greater portion of the estimated $50 billion Australian eCommerce opportunity.

Furthermore, once integrated into Cirralto’s Spenda ecosystem, Greenshoots will be rebranded as Spenda eCommerce — offering Spenda payment services to its customers natively. If the Cirralto share price is anything to go by, investors appear optimistic for this development.

The transaction is on a 100% all-scrip basis, with Cirralto paying an upfront consideration of $1.5 million. Additionally, a further $3.6 million will be contingent on product delivery and revenue milestones being achieved.

Importantly, the acquisition will add a plethora of eCommerce functionality. This includes multi-channel sales and fulfilment management; integration services and workflows with freight providers and 3PLs; and access to global markets.

CEO commentary

Commenting on the acquisition, Cirralto CEO Mr Adrian Floate stated:

The acquisition of Greenshoots into the Cirralto product portfolio will enable us to immediately service businesses looking for an integrated, powerful eCommerce solution.

Unlike other eCommerce providers, the integration behind the Greenshoots solution means we can essentially ‘plugin and play’ the service with our existing Spenda solution. The benefit to customers is huge, not only are they able to sell online, take payment and transact smoothly, but the capabilities of Greenshoots IP mean we are able to push out our inside sales feature and delivery partnership channels at an accelerated pace.

Cirralto share price snapshot

The past 12 months have been a rollercoaster ride for shareholders. The Cirralto share price has been as low as 2.9 cents a share and as high as 21 cents a share.

Fortunately, shareholders have enjoyed a 78% gain over the past year. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) returned 25.4% during the same period.

The post Cirralto (ASX:CRO) share price lifts on Greenshoots acquisition appeared first on The Motley Fool Australia.

More reading

• Why this broker sees 11% upside in the Telstra (ASX:TLS) share price
• Creso (ASX:CPH) share price edges 4% higher following export deal
• Crown (ASX:CWN) share price seesaws amid mandatory vaccination policy
• Why the Atomo Diagnostics (ASX:AT1) share price has soared 30% in a week
• Why the Telix (ASX:TLX) share price is rocketing 6% today

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3nt9m9M

The Crown Resorts Ltd (ASX: CWN) share price is wobbling today. It comes after reports the company is looking at implementing a mandatory COVID vaccination policy for all its staff and visitors to its sites.

At the time of writing, shares in the casino operator are trading for $9.59 — down 0.31%. However, they have been as high as $9.72 in morning trade. The S&P/ASX 200 Index (ASX: XJO), meanwhile, is 0.25% lower.

Let’s take a closer look at today’s news.

Jab for a job

Crown Resorts has announced a “more proactive stance” on jabs and is now mandating it rather than encouraging it among their employees. This news has received a mixed reception from investors – at least, by looking at the Crown share price alone.

According to reports, the group’s CEO, Steve McCann, is in talks with his workforce and government departments to create a plan for a vaccine rollout at the company’s three locations in Sydney, Melbourne, and Perth. While the company has not said it will mandate inoculation for patrons, it has not ruled it out either.

In a statement, Crown said it will begin to “urgently consult its stakeholders and employees regarding mandatory vaccination which could apply to all its staff and members of the public who plan to visit or stay at any of its resorts around Australia”.

A recent survey conduct by Crown management reportedly shows 60% of its employees were already either fully or partially vaccinated.

Management commentary

McCann said of today’s announcement:

At Crown, we care about creating a safe environment for our people and our customers. As such a significant hospitality employer in Australia with resorts that hosted over 30 million visits a year pre-Covid, we need to take measures to help keep people safe. That starts with our employees but also extends to our guests and the broader community.

Covid-19 has devastated the hospitality industry, and that has been felt acutely by our people. Supporting the vaccination target rates set by governments is going to help our industry reopen, stay open and recover faster so we will play our part to help our industry get there. We will continue to explore ways to make it faster and easier for our people to come back to work.

Crown share price snapshot

The Crown share price has had a difficult time recently. All the gains the company saw when first approached about a potential takeover have been wiped out as controversy and uncertainty continue to surround the business.

The Victorian Royal Commission into Crown’s gaming licence is due to hand down its findings next month. One option being considered is revoking said licence.

The Crown share price is down 3% year to date but has gained almost 5% over the past 12 months.

Crown Resorts has a market capitalisation of $6.5 billion.

The post Crown (ASX:CWN) share price seesaws amid mandatory vaccination policy appeared first on The Motley Fool Australia.

More reading

• Crown (ASX:CWN) share price outperforms despite auditor concerns
• Crown (ASX:CWN) share price slumps as problem gambler lawsuit heats up
• How does the Crown Resorts (ASX:CWN) earnings result compare to Star Entertainment (ASX:SGR)?
• Crown Resorts (ASX:CWN) share price slumps amid dividend suspension
• Crown (ASX:CWN) share price wobbles as profit slumps 429%

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/2VCLS6D

The Atomo Diagnostics Ltd (ASX: AT1) share price has gone berserk in the past week.

In the last 7 days, shares in the medical device company have soared more than 30%.

Let’s take a look at why the Atomo share price is flying.

Demand for rapid testing fuelling Atomo share price

In the past week, Atomo has not released any price-sensitive news that could explain the bullish price action.

As a result, various other catalysts could be fuelling investor demand for the company’s shares.

With the Delta outbreak threatening to get out of hand in Australia, there has been increasing demand for rapid testing solutions.

Australia has largely relied on pathology testing in fighting the COVID-19 pandemic.

However, various sources have reflected concern on their turnaround time for results.

Pathology testing can take up to three days to deliver a result, by comparison, rapid antigen tests can detect COVID-19 in as little as 10 minutes.

Atomo is one of the few listed companies in Australia that has produced rapid COVID-19 testing.

Of particular interest is the company’s rapid antibody test CareStart EZ COVID-19, which was developed in conjunction with its partner Access Bio.

Earlier this year, Access Bio received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for point-of-care use of its CareStart EZ COVID-19 test.

The biotech has supplied its CareStart EZ COVID-19 test to various Olympic and sporting teams, whilst also supplying aged care providers.

More on Atomo

Atomo is a medical device company that supplies rapid diagnostic test devices to the global diagnostic market. The company’s patented devices simplify testing procedures and enhance useability for professional users.

The biotech recently published its full-year results for FY21, which was highlighted by a 25.1% increase in revenue to $6.72 million.

Other highlights from Atomo’s report included;

• Cost of sales up 52% to $3.3 million
• Gross profit up 7% to $3.42 million
• Underlying operating loss widened 101% to $4.79 million
• Cash balance of ~$18 million

According to Atomo, revenue was largely driven by consumer demand in Europe and North America for its COVID-19 antibody tests.

At the time of writing, shares in Atomo are trading slightly lower for the day at 28 cents.

The post Why the Atomo Diagnostics (ASX:AT1) share price has soared 30% in a week appeared first on The Motley Fool Australia.

More reading

• Atomo Diagnostics (ASX:AT1) share price sinks 8% on FY21 results

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3lkzYY2

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is up almost 6% in early trade.

Below, we take a look at the ASX biotechnology company’s announcement of its approval to conduct a clinical trial.

What did Telix announce?

The Telix share price is up 5.94% this morning to $6.96 after the company reported positive progress for its investigational kidney cancer therapy, TLX250.

In another step forward for TLX250, the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) to commence a clinical study of the experimental treatment.

Telix expects to enrol 29 patients with advanced clear cell renal cell carcinoma (ccRCC) in its STARLITE 2 study. The goal of the study is to determine the efficacy of combining immunotherapy with TLX250.

Commenting on the study, principal investigator Darren Feldman said:

Each year 76,000 Americans will be diagnosed with kidney cancer, therefore it is important we continue to explore new treatment options. The selective targeting of TLX250 to CA9 delivers radiation therapy directly to ccRCC tumours. Combining this innovative approach with anti-PD-1/PD-L1 therapy could enhance existing immune-based treatments.

Telix chief medical officer Colin Hayward added:

The introduction of immunotherapy agents has improved the outlook for patients with advanced clear cell renal cancer, but most patients eventually progress. This therapy, along with patient selection and treatment response assessment with our CA9-targeting imaging agent TLX250-CDx may potentially offer a new paradigm of more accurate staging and personalised treatment for kidney cancer patients through a “theranostic” approach.

Today’s FDA approval comes on the heels of yesterday’s announcement revealing that Telix had “entered into an exclusive commercial distribution agreement with Bologna-based Radius” to distribute Illuccix – a cancer imaging tool – in Italy.

Telix share price snapshot

Over the past 12 months the Telix share price has soared 279%, well outpacing the 27% gains posted by the All Ordinaries Index (ASX: XAO).

Telix shares have continued to move higher over the past month, up 21%.

The post Why the Telix (ASX:TLX) share price is rocketing 6% today appeared first on The Motley Fool Australia.

More reading

• Why the Telix (ASX:TLX) share price is charging higher today
• Telix Pharmaceuticals (ASX:TLX) share price up 7% on revenue increase
• Telix (ASX:TLX) share price jumps 7% on major Merck collaboration

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3lf0im8

The Propel Funeral Partners Ltd (ASX: PFP) share price is edging higher on Tuesday after the company announced three material acquisitions.

At the time of writing, the Propel Funeral Partners share price is up 5.54%% to $4.00.

What did Propel acquire?

Propel announced this morning that it has executed binding sale agreements to acquire three funeral services businesses.

The three businesses include:

• Berry Funeral Directors located in Norwood, Adelaide
• Glenelg Funerals located in Glenelg, Adelaide
• State of Grace which operates from two locations in Auckland

Together, the businesses perform approximately 1,200 funerals per annum and generated combined revenue of $9.0 million in the most recent financial year. Propel Funeral Partners expects the acquisition to be earnings accretive in year one.

Propel will acquire the three businesses and related assets and infrastructure for a total consideration of up to $17.6 million.

According to the announcement, $15.2 million in cash and $0.2 million in shares (subject to escrow arrangements) will be paid on the completion of the proposed transactions.

In addition, $2.2 million will be payable in cash if certain financial milestones are achieved during the three years following the acquisition.

The acquisition will be funded by existing debt facilities.

The acquisition will expand the company’s network in Australia and New Zealand. It will also drive entry into a new metropolitan market in Adelaide and expand its presence in Auckland.

Excluding the acquisition, Propel Funeral Partners currently operates 136 locations across Australia and New Zealand. This includes 2 sites in South Australia and 25 in New Zealand.

Propel Funeral Partners share price snapshot

The Propel Funeral Partners share price has rallied strongly in 2021, up 40% year-to-date.

The post Propel Funeral Partners (ASX:PFP) share price lifts 5% on acquisition news appeared first on The Motley Fool Australia.

More reading

• 2 ASX dividend shares that just grew their dividend by more than 10%
• The Propel Funeral Partners (ASX:PFP) share price lifts 5% on FY21 performance

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Propel Funeral Partners Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3AdCVQj